Role of subconjunctival injection of Bevacizumab (Anti VEGF) for Corneal Neovascularisation,after cornea Transplant
Phase 2
- Conditions
- Health Condition 1: - Health Condition 2: H598- Other intraoperative and postprocedural complications and disorders of eye and adnexa, not elsewhere classified
- Registration Number
- CTRI/2021/10/037416
- Lead Sponsor
- SNMedical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)patients having 2 or more than 2 quadrant corneal neovascularisation
2)patients who developed corneal neovascularisation during F/U ,not responding to conventional medical treatment .
3)patients who gave consent to be in follow up.
Exclusion Criteria
1)patients having persistent epithelial defect
2)patients who were systemically not fit for subconj Bevacizumab injection;pts with H/O recent attack of M.I.,stroke and uncontrolled Hypertension.
3)pregnant female
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Corneal Neovascularization ParametersTimepoint: Follow up at an interval of one month after first dose of subconjunctival Bevacizumab till the completion of study period
- Secondary Outcome Measures
Name Time Method Graft clarity,CCT and visual acuityTimepoint: Follow up at an interval of one month after first dose of subconjunctival Bevacizumab till the completion of study period